Hypertension Clinical Trial
— CAPACITYOfficial title:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Verified date | October 2023 |
Source | United Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment
Status | Terminated |
Enrollment | 10 |
Est. completion date | April 12, 2023 |
Est. primary completion date | April 12, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent form. 2. At least 18 years of age. 3. Primary diagnosis of PAH. 4. Has had a diagnostic RHC performed at or within 3 years before Screening (or at Screening if one is not available) that is consistent with the diagnosis of PAH. 5. Has World Health Organization (WHO)/New York Heart Association (NYHA) Functional Class (FC) II to III symptoms 6. Must be on a stable dose of PAH-specific oral therapy, defined as no change in dose or regimen for at least 90 days prior to randomization. Allowable PAH-specific therapy is an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor (PDE5-I) or a soluble guanylate cyclase (sGC) stimulator. Subjects may be on a stable dose of either a PDE5-I or a sGC stimulator, not both. 7. Has a 6-minute walk distance (6MWD) of =150 meters at Screening. 8. Has a peak VO2 of =9 to <18 mL/min/kg during the Screening CPET, as assessed by the CPET core laboratory. 9. If the subject is taking concomitant medications that may affect the clinical manifestations of PAH, the subject must be on a stable dose for at least 30 days prior to randomization. The exception is that the dose of diuretics must be stable for at least the 10 days prior to randomization. 10. Both male and female subjects agree to use a highly effective method of birth control throughout the entire study period from informed consent through to the Week 28 Visit/28-day Follow-up Visit, if the possibility of conception exists. Eligible male and female subjects must also agree not to participate in a conception process during the study and for 30 days after the final dose of study drug. Eligible male subjects must agree not to participate in sperm donation for 90 days after the final dose of study drug. Women who are surgically sterile or postmenopausal are not considered to be of childbearing potential. If of childbearing potential, female partners of male study participants should agree to utilize medically acceptable methods of contraception for the duration of study participation. Exclusion Criteria: 1. For subjects with known human immunodeficiency virus-associated PAH, a cluster of differentiation 4 T-cell count <200/mm3 at Screening. 2. Has 3 or more left ventricular disease/dysfunction risk factors. 3. Symptomatic coronary artery disease and/or myocardial infarction within past 6 months. 4. Current symptomatic aortic or mitral valve disease. 5. Has evidence of more than mild lung disease on pulmonary function tests performed within 1 year prior to, or during, Screening. 6. Has evidence of thromboembolic disease as determined by ventilation-perfusion lung scan or local standard of care diagnostic evaluation at or after diagnosis of PAH. 7. Current diagnosis of ongoing and clinically significant sleep apnea as defined by the Investigator. 8. Requires use of supplemental oxygen during CPET. 9. Respiratory exchange ratio <1.0 at Screening CPET as determined by the CPET core laboratory. 10. Acute non-cardiac disorder that may affect exercise performance or be aggravated by exercise (eg, infection, renal failure, thyrotoxicosis). 11. Male subjects with a QTcF >450 msec and female subjects with a QTcF >470 msec on electrocardiogram (ECG) recorded at Screening and analyzed by the central ECG laboratory. Subjects with evidence of intraventricular conduction delay, defined as a QRS interval >110 msec, will be excluded if QTcF is >500 msec for both males and females. 12. Severe chronic liver disease (ie, Child-Pugh Class C), portal hypertension, cirrhosis, or complications of cirrhosis/portal hypertension (eg, history of variceal hemorrhage, encephalopathy). 13. Confirmed active infection with hepatitis B virus or hepatitis C virus. 14. Subjects with alanine aminotransferase or aspartate aminotransferase =3 times the upper limit of normal or total bilirubin =2 times the upper limit of normal at Screening. 15. Chronic renal insufficiency as defined by an estimated glomerular filtration rate using the Modification of Diet in Renal Disease Study equation of <30 mL/min/1.73 m2 or requiring dialysis at Screening. 16. Hemoglobin concentration <9 g/dL at Screening. 17. Subjects treated with an intravenous, subcutaneous, inhaled, or oral prostacyclin pathway agent (eg, epoprostenol, treprostinil, iloprost, beraprost, or selexipag) for PAH within 90 days of randomization (use in vasoreactive testing is permitted). Subject is not eligible if previous prostacyclin therapy was stopped for a safety or tolerability issue related to systemic prostacyclin adverse effects. 18. Subject has pulmonary veno-occlusive disease. 19. Malignancy diagnosed and/or treated within 3 years of Screening, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent. 20. Subject tests positive for amphetamine, cocaine, methamphetamine, methylenedioxymethamphetamine, or phencyclidine in urine drug screen performed at Screening, or has a recent history (6 months) of alcohol or drug abuse. Subjects will not be excluded due to a positive drug screen caused by prescribed medications. 21. Initiation or discontinuation of a cardio-pulmonary rehabilitation program based upon exercise within 90 days prior to Screening and/or planned during study participation. 22. Prior participation in any study of ralinepag or another interventional clinical study with medicinal products within 30 days prior to Screening. Concurrent participation in registry or observational studies is allowed, if the subject can fulfill all other entry criteria and comply with all study procedures. 23. Any reason that, in the opinion of the Investigator, precludes the subject from participating in the study (eg, any previous or intercurrent medical condition) that may increase the risk associated with study participation or that would confound study analysis (eg, right-to-left shunt detected during CPET) or impair study participation or cooperation. 24. Known hypersensitivity to ralinepag or any of the excipients. 25. Life expectancy <12 months based on the Investigator's opinion. 26. Women who are pregnant, lactating, or breast-feeding. |
Country | Name | City | State |
---|---|---|---|
Argentina | Hospital Britanico de Buenos Aires | Ciudad Autónoma de Bs. As. | |
Argentina | Instituto de Cardiología de Corrientes | Corrientes | |
Australia | The Prince Charles Hospital | Chermside | Queensland |
Australia | Macquarie University | North Ryde | New South Wales |
Australia | Westmead Hospital, Dept Respiratory and Sleep Medicine | Westmead | New South Wales |
Australia | Princess Alexandra Hospital | Woolloongabba | Queensland |
Austria | Ordensklinikum Linz GmbH, Elisabethinen | Linz | |
Austria | AKH Wien, Innere Med. II, Kardiologie | Vienna | |
Belgium | Erasme University Hospital - Department of Cardiology | Brussels | |
Belgium | Gasthuisberg University Hospital - Department of Pulmonology | Leuven | |
Brazil | Hospital Madre Teresa | Belo Horizonte | MG |
Brazil | Centro de Hipertensão Pulmonar | Porto Alegre | |
Brazil | Hospital Sao Paulo | São Paulo | SP |
Brazil | Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo - InCor-HCFMUSP | São Paulo | SP |
Canada | Peter Lougheed Center | Calgary | Alberta |
Canada | University of Alberta Hospital | Edmonton | Alberta |
Canada | London Health Science Centre- Victoria Hospital | London | Ontario |
Germany | Universitätsklinikum Carl Gustav Carus TU Dresden, Medizinische Klinik I, Abteilung für Pneumologie | Dresden | Sachsen |
Germany | Thoraxklinik-Heidelberg, Zentrum für Pulmonale Hypertonie | Heidelberg | Baden-Wurttemberg |
Italy | Centro Cardiologico Monzino, IRCCS | Milano | |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milano | |
Italy | AOU Policlinico Umberto I | Rome | |
Poland | Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Kardiologii z Oddzialem Intensywnego Nadzoru Kardiologicznego | Bialystok | |
Poland | Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Oddzial Kardiologiczny | Otwock | |
Spain | Hospital Clínic I Provincial de Barcelona | Barcelona | |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
United Kingdom | Imperial college Healthcare NHS Trust | London | |
United States | University of Colorado Anschutz Medical Campus | Aurora | Colorado |
United States | National Jewish Health | Denver | Colorado |
United States | Medical College of Wisconsin/Froedtert Hospital | Milwaukee | Wisconsin |
United States | Tampa General Hospital/University of South Florida Center for Advanced Lung Disease and Lung Transplant | Tampa | Florida |
United States | Banner University Medical Center (University of Arizona) | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
United Therapeutics |
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Germany, Italy, Poland, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in peak VO2 assessed by CPET | Peak VO2 by CPET was measured at Baseline (prior to starting study drug) and Week 28 | Baseline to Week 28 | |
Secondary | Change from Baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP) | NT-proBNP was measured at Baseline (prior to starting study drug) and Weeks 4, 8, 12, 16, 20, 24 and 28 | Baseline to Week 28 | |
Secondary | Change from Baseline in Minute Ventilation (VE)/Carbon Dioxide output (VCO2) slope | VE/VCO2 slope (from CPET) was calculated at Baseline (prior to starting study drug) and Week 28 | Baseline to Week 28 | |
Secondary | Change from Baseline in health-related quality of life measured by the Short Form Health Survey (SF-36) Scores | SF-36 was assessed at Baseline (prior to starting study drug) and Weeks 16 and 28. The SF-36 consisted of 36 questions in 8 health categories (Vitality, Physical Functioning, Bodily Pain, General Health Perception, Role Physical, Role Emotional, Social Functioning, and Mental Health). Responses to the questions were graded on a numerical scale, with 1 as the best score and higher numbers as worse scores. The raw scores from the subscales were converted and summed by the Investigator to a total score between 0 and 100 to measure functional health and well-being from the patient's point of view. The final score range was 0 (representing the lowest possible score; worst health state) to 100 (representing the highest possible score; best health state). | Baseline to Week 28 | |
Secondary | Time to First All-cause Non-elective Hospitalization | The time to first all-cause nonelective hospitalization during the study period will be assessed. | Baseline to Week 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |